Cytori Therapeutics (NASDAQ:CYTX) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02), Bloomberg Earnings reports. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.00 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%.
Shares of Cytori Therapeutics (NASDAQ:CYTX) remained flat at $$0.32 during trading hours on Friday. 1,431,971 shares of the company’s stock were exchanged, compared to its average volume of 1,240,000. The firm has a market cap of $11.06, a PE ratio of -0.36 and a beta of 3.49. Cytori Therapeutics has a one year low of $0.22 and a one year high of $2.08.
A number of equities research analysts have recently weighed in on the company. B. Riley upgraded Cytori Therapeutics from a “neutral” rating to a “buy” rating in a research report on Friday. Maxim Group set a $2.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research lowered Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Laidlaw restated a “buy” rating and set a $1.65 price target on shares of Cytori Therapeutics in a research report on Thursday, February 22nd. Finally, ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $1.80.
An institutional investor recently raised its position in Cytori Therapeutics stock. Vanguard Group Inc. lifted its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 612,304 shares of the biotechnology company’s stock after purchasing an additional 275,653 shares during the quarter. Vanguard Group Inc. owned 1.89% of Cytori Therapeutics worth $674,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.57% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3253991/cytori-therapeutics-cytx-posts-earnings-results-misses-expectations-by-0-02-eps.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.